ArticleClinical pharmacology : advances and applications2025
Parametric Population Pharmacokinetics Model Repository of Rifampicin: Model-Informed Individualized Therapy.
Article in Clinical pharmacology : advances and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A population pharmacokinetic model library for polymyxin B: clinical implementation of model-informed precision dosing.Frontiers in pharmacology · 2026Article
- Bridging Literature and Real-World Evidence: External Evaluation and Development of Fluoxetine Population Pharmacokinetics Model.Pharmaceutics · 2025Article
- A Step Toward Precision Dosing of Escitalopram in Chinese Patients: An External Evaluation of Published Population Pharmacokinetic Models.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rifampicin is a crucial first-line anti-tuberculosis drug that has been extensively studied through population pharmacokinetic (popPK) analyses. This study aims to construct a comprehensive rifampicin popPK model repository to support model-informed individualized therapy. Methods: A systematic review was conducted using PubMed, Web of Science, and Embase databases up to September 2023 to retrieve popPK model articles on rifampicin. Extracted data included basic information, dosing regimens, sampling strategies, model parameters, and covariate details. Non-English studies, non-parametric models, and duplicates were excluded. The repository was built using R package mrgsolve, and a Shiny application was developed for simulation and individualized dosing predictions. Results: A total of 29 studies were included in the rifampicin model repository: 23 on adults, 5 on pediatrics, 1 on both populations, and 1 on pregnant women. Most rifampicin popPK models were one-compartment linear elimination models, with transit compartment or lagged absorption models improving drug absorption fitting. An allometric growth model based on fat-free mass (FFM) might improved model fit. Postmenstrual age (PMA) significantly impacted elimination in pediatric patients. All models underwent internal validation, with three studies validated externally. Significant variations in exposure predictions were observed among models, indicating challenges in achieving therapeutic targets under standard treatment. Discussion: The model repository provides a comprehensive resource for exploring various models and their application in different populations, supporting individualized rifampicin therapy. Further research is needed for special populations and to determine whether weight or FFM is more rational for dosing. External validation is essential for model development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.